the New Geneswell BCT in Vitro Diagnosis of Breast Cancer Prognosis

Second Affiliated Hospital, Zhejiang University, School of Medicine100 enrolled

Overview

Geneswell BCT is a precise and qualitative in vitro diagnostic test. The expression of 9 genes was obtained from the formalin fixed paraffin embedded block (FFPE) of breast cancer tissue samples by RT-qPCR, and the patients were divided into high-risk group and low-risk group. This test provides prognostic information to assess the risk of recurrence. The BCT score calculated by geneswell BCT was associated with the risk of recurrence. The higher the BCT score, the more likely it is to relapse, and vice versa.

Study Type

OBSERVATIONAL

Enrollment

100

Conditions

Breast Cancer

Interventions

Geneswell BCTDIAGNOSTIC_TEST

Eligibility

Sex: FEMALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * The patients were diagnosed with invasive breast cancer with positive hormone receptor (including positive estrogen receptor or progesterone receptor) and negative human epidermal growth factor receptor 2 (HER2) * Axillary lymph node assessment : pN0 or PN1 * Women aged 18 and over * Patients without chemotherapy after operation Exclusion Criteria: * Patients with negative hormone receptor （both estrogen and progesterone receptor are negative） * Human epidermal growth factor receptor 2 （HER2） positive * Pathological nodule evaluation: pN2 or pN3 * Male patients * Patients receiving chemotherapy after surgery

Outcomes

Primary Outcomes

Comparative assessment between risk groups

By evaluating the 5-year disease-free survival rate (DFS) of patients in high and low risk groups, the statistical differences between the two groups were compared.

Time frame: Month 9

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.